Astellas Submits New Drug Applications for Approval of Gilteritinib for the Treatment of FLT3mut+ Relapsed or Refractory Acute Myeloid Leukemia

TOKYO, April 23, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., " Astellas " ) today announced that it submitted on March 23, 2018, a new drug application (NDA) for marketing approval of gilteritinib...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news

Related Links:

Overall survival 1.5 months; survival improved for those receiving chemotherapy
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pharmacy, Geriatrics, Journal, Source Type: news
To characterize intracellular signaling in peripheral blood (PB) cells of acute myeloid leukemia (AML) patients undergoing pretransplant conditioning with CXCR4 inhibitor plerixafor, granulocyte colony-stimulating factor (G-CSF), and busulfan plus fludarabine (Bu+Flu) chemotherapy, we profiled 153 proteins in 33 functional groups using reverse phase protein array. CXCR4 inhibition mobilized AML progenitors and clonal AML cells, and this was associated with molecular markers of cell cycle progression. G-CSF/plerixafor and G-CSF/plerixafor/Bu+Flu modulated distinct signaling networks in AML blasts of patients undergoing cond...
Source: Acta Haematologica - Category: Hematology Source Type: research
ConclusionsVosaroxin and venetoclax synergistically induce apoptosis in acute myeloid leukemia cells and cooperatively target acute myeloid leukemia progenitor cells while sparing normal hematopoietic progenitor cells. Our results support the clinical testing of vosaroxin in combination with venetoclax for treating patients with acute myeloid leukemia, especially in the elderly population.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
Condition:   Adult Acute Myeloid Leukemia in Remission Intervention:   Biological: Alloreactive NK cell infusion Sponsor:   Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Adult Acute Myeloid Leukemia in Remission Intervention:   Biological: Alloreactive NK cell infusion Sponsor:   Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
We present a case of a 19-month infant who was taken to the Emergency Department due to fever and a gingival lesion that did not respond to antibiotic treatment. An ultrasound study was requested to assess the presence of an abscess. However, a lesion was identified and after performing a biopsy, pathologist found it was a myeloid sarcoma. The patient was diagnosed with AML and chemotherapy treatment was started. After three cycles of treatment, the patient is currently free of disease.
Source: Revista Espanola de Cirugia Oral y Maxilofacial - Category: ENT & OMF Source Type: research
We present a case of a 19-month infant who was taken to the Emergency Department due to fever and a gingival lesion that did not respond to antibiotic treatment. An ultrasound study was requested to assess the presence of an abscess. However, a lesion was identified and after performing a biopsy, pathologist found it was a myeloid sarcoma. The patient was diagnosed with AML and chemotherapy treatment was started. After three cycles of treatment, the patient is currently free of disease.
Source: Revista Espanola de Cirugia Oral y Maxilofacial - Category: ENT & OMF Source Type: research
Acute myeloid leukemia (AML) is a heterogeneous disease in terms of genetic basis, clinical, biological and prognostic, and is a malignant clonal disease of leukemia stem cells (LSCs). Nearly half of adult AML...
Source: Journal of Translational Medicine - Category: Research Authors: Tags: Research Source Type: research
There is an urgent need for novel and effective treatment options for acute myeloid leukemia (AML). Triptolide, a diterpenoid tri-epoxide compound isolated from the herb Tripterygium wilfordii and its water-solub...
Source: Journal of Translational Medicine - Category: Research Authors: Tags: Research Source Type: research
AbstractThe development of allogeneic hematopoietic-stem-cell transplantation has improved the prognosis of younger acute myeloid leukemia (AML) patients. However, the outcome of older AML patients remains poor. The majority of AML patients are elderly. For elderly AML patients unfit for intensive chemotherapy, less toxic single agent that targets a specific gene mutation or combination therapy with a single agent is needed. The role of chromosomal abnormalities and genetic mutations in leukemia has become more apparent, and detailed prognostic stratification based on the type of genetic mutation has been established. Next...
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Drugs & Pharmacology | Leukemia | Marketing | New Drug Applications | Pharmaceuticals